Photo de profil par défault

Brigitte Kerfelec

Publications
Dec 2015 Antibodies (Basel, Switzerland)

Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?

Del Bano J, Chames P, Baty D, Kerfelec B

Apr 2019 Biophysical journal

Nanobody-CD16 Catch Bond Reveals NK Cell Mechanosensitivity.

González C, Chames P, Kerfelec B, Baty D, Robert P, Limozin L

Jan 2019 Frontiers in immunology

A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer.

Del Bano J, Florès-Florès R, Josselin E, Goubard A, Ganier L, Castellano R, Chames P, Baty D, Kerfelec B

Jul 2018 Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Preclinical Evaluation of Mesothelin-Specific Ligands for SPECT Imaging of Triple-Negative Breast Cancer.

Montemagno C, Bacot S, Ahmadi M, Kerfelec B, Baty D, Debiossat M, Soubies A, Perret P, Riou L, Fagret D, Broisat A, Ghezzi C

Jul 2015 Journal of biomedical nanotechnology

Anti-Mesothelin Nanobodies for Both Conventional and Nanoparticle-Based Biomedical Applications.

Prantner AM, Turini M, Kerfelec B, Joshi S, Baty D, Chames P, Scholler N

Jul 2014 Oncotarget

A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy.

Turini M, Chames P, Bruhns P, Baty D, Kerfelec B

Feb 2014 Molecular & cellular proteomics : MCP

Masked selection: a straightforward and flexible approach for the selection of binders against specific epitopes and differentially expressed proteins by phage display.

Even-Desrumeaux K, Nevoltris D, Lavaut MN, Alim K, Borg JP, Audebert S, Kerfelec B, Baty D, Chames P

Aug 2013 Molecular cancer therapeutics

Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells.

Rozan C, Cornillon A, Pétiard C, Chartier M, Behar G, Boix C, Kerfelec B, Robert B, Pèlegrin A, Chames P, Teillaud JL, Baty D

Jun 2010 TheScientificWorldJournal

Therapeutic antibodies for the treatment of pancreatic cancer.

Chames P, Kerfelec B, Baty D